Australia markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
883.20-7.48 (-0.84%)
At close: 04:00PM EDT
881.21 -1.99 (-0.23%)
After hours: 04:36PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 96.94B
Enterprise value 88.80B
Trailing P/E 25.40
Forward P/E 19.65
PEG ratio (5-yr expected) 1.42
Price/sales (ttm)7.66
Price/book (mrq)3.73
Enterprise value/revenue 6.77
Enterprise value/EBITDA 18.92

Trading information

Stock price history

Beta (5Y monthly) 0.14
52-week change 39.48%
S&P500 52-week change 322.36%
52-week high 3998.33
52-week low 3684.81
50-day moving average 3947.85
200-day moving average 3863.98

Share statistics

Avg vol (3-month) 3467.06k
Avg vol (10-day) 3484.58k
Shares outstanding 5107.94M
Implied shares outstanding 6109.76M
Float 8102.75M
% held by insiders 12.58%
% held by institutions 189.32%
Shares short (15 Apr 2024) 41.39M
Short ratio (15 Apr 2024) 43.05
Short % of float (15 Apr 2024) 41.50%
Short % of shares outstanding (15 Apr 2024) 41.26%
Shares short (prior month 15 Mar 2024) 41.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 30.14%
Operating margin (ttm)29.20%

Management effectiveness

Return on assets (ttm)8.49%
Return on equity (ttm)16.26%

Income statement

Revenue (ttm)13.12B
Revenue per share (ttm)122.93
Quarterly revenue growth (yoy)0.60%
Gross profit (ttm)N/A
EBITDA 4.65B
Net income avi to common (ttm)3.95B
Diluted EPS (ttm)34.80
Quarterly earnings growth (yoy)-3.10%

Balance sheet

Total cash (mrq)10.84B
Total cash per share (mrq)100.92
Total debt (mrq)2.79B
Total debt/equity (mrq)10.74%
Current ratio (mrq)5.69
Book value per share (mrq)242.47

Cash flow statement

Operating cash flow (ttm)4.59B
Levered free cash flow (ttm)2.76B